Cost-effectiveness Evaluation of Vector Control Strategies in Mozambique
NCT02910934 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 3915
Last updated 2020-09-17
Summary
This study aims to provide National Malaria Control Programs (NMCP), international donors and other key stakeholders with clear evidence on the impact and cost-effectiveness of using indoor residual spraying (IRS) with a non-pyrethroid insecticide in a high malaria transmission area that has universal long-lasting insecticidal net (LLIN) coverage. This is an interventional study with IRS serving as the research intervention.
The district of Mopeia, in the province of Zambezia, Mozambique will be the study site. This is a high transmission area with a malaria parasite prevalence of 54% in children. The Ministry of Health distributed LLINs in Mopeia in 2014-2015.
The NMCP through funding from President's Malaria Initiative Africa Indoor Residual Spraying Project (PMI-AIRS) was able to cover half a district with indoor residual spraying. A simplified census took place in mid-2016 to determine the number of children five years of age and under in the district and enumerate and map the households to assist in implementation.
From the 115 villages/bairros existent in Mopeia, 86 clusters were randomized in a government randomization ceremony to either receive IRS with Actellic or maintain no IRS. The IRS was implemented through a partnership between the NMCP and PMI-AIRS according to standard operational and consent procedures. From each cluster, a cohort of 18 children five years of age and under will be followed monthly to assess malaria incidence at the community level in both IRS and non-IRS villages. There will be 774 children in the IRS villages and 774 children in the no-IRS villages (total cohort will be 1548). Additionally, the routine health centre reporting system will be strengthened to assess malaria incidence in children five years of age and under by passive case detection. Three cross sectional studies in April 2017, April 2018, and April 2019 will assess changes in net use, health seeking behaviour and malaria prevalence at the community level.
Entomological data will be collected from both IRS and non-IRS areas to assess the vector dynamics and insecticide resistance pattern of the local vector populations from sprayed and unsprayed areas. Data on the costs of the implementation as well as health-related expenditures at health system and household levels will be collected prospectively throughout the study. These costs will be determined using both health system and societal perspectives.
The incidence rate in IRS and no-IRS areas will be combined with the micro-costing data to calculate the cost per case averted at community and health facility level.
These findings will be disseminated to the NMCP and international donors and stakeholders to complement the World Health Organization (WHO) guidance on combining indoor residual spraying and long-lasting insecticidal nets.
Conditions
Interventions
- OTHER
-
Actellic CS
Indoor residual spray with Actellic CS
Sponsors & Collaborators
-
United States Agency for International Development (USAID)
collaborator FED -
Abt Associates
collaborator INDUSTRY -
Centers for Disease Control and Prevention
collaborator FED -
Ministry of Health, Mozambique
collaborator OTHER_GOV -
Centro de Investigacao em Saude de Manhica
collaborator OTHER -
PATH
lead OTHER
Principal Investigators
-
Francisco Saute, Md, MSc, PhD · Centro de Investigacoes de Manhica
-
Molly Robertson, MA, MPH · PATH
-
Carlos Chaccour, MD, MSc, PhD · Barcelona Institute for Global Health
-
Rose Zulliger, PhD · US Presidents Malaria Initiative, Centers for Disease Control and Prevention
-
Abuchama Saifodine, PhD · US Presidents Malaria Initiative, USAID
Study Design
- Allocation
- RANDOMIZED
- Purpose
- HEALTH_SERVICES_RESEARCH
- Masking
- SINGLE
- Model
- PARALLEL
Eligibility
- Min Age
- 6 Months
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2017-01-10
- Primary Completion
- 2019-12-31
- Completion
- 2019-12-31
Countries
- United States
- Mozambique
Study Locations
More Related Trials
-
The Effectiveness of Non-Pyrethroid Insecticide-Treated Durable Wall Liners as a Method for Malaria Control in Endemic Rural Tanzania
NCT02533336 ·Status: TERMINATED ·Phase: PHASE3
-
Study of Controlled Human Malaria Infections to Evaluate Protection After Intravenous or Intramuscular Administration of PfSPZ Vaccine in Malaria-Naive Adults
NCT02015091 ·Status: COMPLETED ·Phase: PHASE1
-
Implementation Research of New Dengue Vector Control Tools
NCT00883441 ·Status: COMPLETED ·Phase: NA
-
Safety of a Single Dose of Moxidectin Compared With Ivermectin in Individuals Living in Onchocerciasis Endemic Areas and in Individuals Living in Onchocerciasis Endemic Areas With High Levels of Lymphatic Filariasis Co-endemicity Receiving Concomitant Albendazole
NCT04311671 ·Status: COMPLETED ·Phase: PHASE3
-
COVID-19 Surveillance in Rural Mozambique for Prompt and Effective Response
NCT05228639 ·Status: COMPLETED
-
Trial to Assess the Efficacy of Malaria Vaccine PfCS 102
NCT01031524 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Attractive Targeted Sugar Bait Trial in Mali
NCT04149119 ·Status: UNKNOWN ·Phase: NA
-
Safety, Immunogenicity, and Protective Efficacy of Radiation Attenuated Plasmodium Falciparum NF54 Sporozoites in Healthy African Adults in Mali
NCT02627456 ·Status: COMPLETED ·Phase: PHASE1
-
Comparison of Two Strategies for Administering the R21-Matrix M Vaccine in a Context of Seasonal Malaria Transmission in Chad
NCT07038837 ·Status: RECRUITING ·Phase: PHASE4
-
An Observational Study to Assess Effectiveness and Safety of The R21/Matrix-M Malaria Vaccine
NCT07009847 ·Status: RECRUITING
-
Repeat Ivermectin Mass Drug Administrations for MALaria Control II
NCT03967054 ·Status: COMPLETED ·Phase: PHASE3
-
Field Evaluations of Innovative Tools for Vector-borne Disease Control in Conflict-affected Communities
NCT06179732 ·Status: COMPLETED ·Phase: PHASE3
-
Sustainable Reduction of Dengue in Colombia: Vector Breeding Site Intervention With an Insecticidal Coating
NCT06268691 ·Status: COMPLETED ·Phase: NA
-
MMV533 Plasmodium Falciparum Volunteer Infection Study
NCT05205941 ·Status: COMPLETED ·Phase: PHASE1
-
A Cluster Randomized Trial to Evaluate Long Lasting Insecticidal Hammocks to Prevent Forest Malaria in Vietnam
NCT00853281 ·Status: COMPLETED ·Phase: NA
-
Experimental PfSPZ Vaccine in Adults Without Malaria
NCT01441167 ·Status: COMPLETED ·Phase: PHASE1
-
Malaria Vaccine Pilot Evaluation
NCT03806465 ·Status: COMPLETED
-
Safety and Protective Efficacy of Pb(PfCS@UIS4)
NCT03138096 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Experimental Vaccine for Plasmodium Falciparum Malaria
NCT00340431 ·Status: COMPLETED ·Phase: PHASE1
-
A Study of the Safety and Effectiveness of Two New Malaria Vaccines
NCT01003314 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Assessing Human-to-Mosquito Transmission in Volunteers Participating in Malaria Vaccine Candidate Trials in Mali
NCT02206451 ·Status: COMPLETED
-
Febrile Disease Landscape in Cambodia Via Metagenomic Pathogen Sequencing
NCT04034264 ·Status: RECRUITING
-
A Study to Evaluate the Safety, Immunogenicity and Efficacy of GlaxoSmithKline (GSK) Biologicals' Candidate Malaria Vaccine RTS,S/AS02A, When Administered to Children Aged 1 to 4 Years Living in a Malaria-endemic Region of Mozambique.
NCT00197041 ·Status: COMPLETED ·Phase: PHASE2
-
Infant Malaria Vaccine Schedule Optimization
NCT06879327 ·Status: RECRUITING ·Phase: PHASE2
-
Chemoprophylaxis and Plasmodium Falciparum NF54 Sporozoite Immunization Challenged by Heterologous Infection
NCT02098590 ·Status: COMPLETED ·Phase: NA